Overexpressed RBPMS-AS1 increased cell radiosensitivity by sponging miR-19a-3p in lung cancer cell lines (A549 and SK-MES-1) via regulating PTEN/AKT axis

Abstract

Purpose

This paper intended to study RBPMS-AS1 in lung cancer (LC) radiosensitivity.

Materials and Methods

LC cells were transfected with RBPMS-AS1 overexpression plasmid and miR-19a-3p mimic and treated with radiation. PTEN, AKT, p-AKT, RBPMS-AS1, and miR-19a-3p expressions were detected via Western blot and qRT-PCR. The localization of RBPMS-AS1 in cells was determined through fluorescence in situ hybridization assay. The targeting relationships of RBPMS-AS1 and miR-19a-3p/miR-19a-3p and PTEN were determined through RIP and dual luciferase reporter analysis. Cell survival, viability, and apoptosis were assessed through colony formation, CCK-8, and flow-cytometry assays.

Results

RBPMS-AS1 was downregulated in LC and mainly distributed in cytoplasm. RBPMS-AS1 targeted miR-19a-3p in LC cells. Radiation suppressed LC cell survival, viability, and induced apoptosis, as overexpressed RBPMS-AS1 performed the similar effects and enhanced those effects induced by radiation. MiR-19a-3p mimic reversed the effect of overexpressed RBPMS-AS1 on enhancing radiation-induced LC cell apoptosis. MiR-19a-3p targeted PTEN and miR-19a-3p mimic reversed the effect of overexpressed RBPMS-AS1 on PTEN and phosphorylation of AKT in LC cells.

Conclusion

Overexpressed RBPMS-AS1 sponged miR-19a-3p to increase cell radiosensitivity in LC via regulating PTEN/AKT axis.

Keywords:

• Lung cancer
• RBPMS-AS1
• MiR-19a-3p
• PTEN/AKT
• radiosensitivity

Disclosure statement

No potential conflict of interest was reported by the authors.

Data availability statement

The analyzed data sets generated during the study are available from the corresponding author on reasonable request.

Additional information

Funding

This work was supported by the Zhejiang Provincial Health Department, General Project [grant number 2021KY1078].

Notes on contributors

Chengyu Ye

Chengyu Ye is a master student of Zhejiang University of Traditional Chinese Medicine, he has published 3 SCI articles and 1 article in a Chinese journal. In 2017, he obtained two patents for utility model technology and won the title of “Excellent Trainee” in Wenzhou Central Hospital.

Quanbing Lin

Quanbing Lin is the chief physician of Radiotherapy Department of Wenzhou Central Hospital, he has been engaged in radiation clinic for more than 20 years and has rich clinical experience in the radiation area.

Cuiping Zheng

Cuiping Zheng is the chief physician of Hematology Chemotherapy Department of Wenzhou Central Hospital, tutor of master students. She has rich clinical experience in chemotherapy, targeted therapy and comprehensive treatment of malignant tumors, and published more than 20 SCI articles. She is a famous doctor in Ouyue, Wenzhou city, and also won 551 first-level talents prize.